Press release
Growth at a high CAGR of 20.2% in the RNA-interference (RNAi) Market during the forecast period| Major Vendors - ALNYLAM PHARMACEUTICALS, BENITEC BIOPHARMA LTD, ISIS PHARMACEUTICALS, RXI PHARMACEUTICALS, QIAGEN, INVITROGEN, AMBION, amongst others
Market Analysis:North America Dominating the Market
North America holds the largest market share of the RNAi market due to large number of companies and research institutes, recent technological & medical advances, growing population and high incidence of diseases, such as liver disorders and cancers.
Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16822
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”
Cancer diagnosis and treatment is currently undergoing a paradigm shift with the incorporation of RNAi techniques in personalized medicines and molecular diagnostics. The availability of high throughput techniques for the identification of altered cellular molecules and metabolites allows the use of RNAi techniques in various cancer diagnosis and targeting approaches. Increasing application of RNAi in molecular diagnosis and its viability as a therapeutic technique is expected to drive the growth of the RNAi market during the forecast period. Additionally, improving synthetic delivery carriers and chemical modifications to RNA are also fuelling the growth of the global RNAi technology market.
Request Discount on this report @ https://marketprognosis.com/discount-request/16822
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”
Market Segments:
RNA-interference (RNAi) Market is segmented by:
1. Application: Drug Discovery & Development, Therapeutics, Others
2. Geography: North America, South America, Europe, Asia Pacific, Middle East & Africa
Key Developments in the Market
• November 2017: Arcturus Therapeutics merged with Alcobra Ltd.
• October 2017: Alnylam and Vir Form Strategic alliance to advance RNAi Therapeutics for infectious diseases.
• October 2017: Arcturus Therapeutics announced strategic collaboration with Johnson & Johnson Innovation to discover and develop RNA medicines.
Enquiry before Buying @ https://marketprognosis.com/enquiry/16822
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”
About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today's complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.
Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Growth at a high CAGR of 20.2% in the RNA-interference (RNAi) Market during the forecast period| Major Vendors - ALNYLAM PHARMACEUTICALS, BENITEC BIOPHARMA LTD, ISIS PHARMACEUTICALS, RXI PHARMACEUTICALS, QIAGEN, INVITROGEN, AMBION, amongst others here
News-ID: 1639672 • Views: …
More Releases from Market Prognosis
Third-Party Logistics (3PL) Market Latest Study Focuses On Current, Future Innov …
The report covers a forecast and an analysis of the Third-Party Logistics (3PL) Market on a global and regional level. The study provides historical data for 2018, 2019, and 2020 along with a forecast from 2019 to 2026 based on revenue and volume.
Overview of the Global Third-Party Logistics (3PL) Market:
The report spread across 90 pages is an overview of the Global Third-Party Logistics (3PL) Market. These report study based on the Third-Party…
Ride-Hailing Market: An Insight on the Important Factors and Trends Influencing …
The report covers a forecast and an analysis of the Ride-Hailing Market on a global and regional level. The study provides historical data for 2018, 2019, and 2020 along with a forecast from 2019 to 2026 based on revenue and volume.
Overview of the Global Ride-Hailing Market:
The report spread across 90 pages is an overview of the Global Ride-Hailing Market. These report study based on the Ride-Hailing Market. It is a complete overview…
COVID-19 Impact on Professional Indemnity Insurance Market 2021-2026: Industry I …
The report covers a forecast and an analysis of the Professional Indemnity Insurance Market on a global and regional level. The study provides historical data for 2018, 2019, and 2020 along with a forecast from 2019 to 2026 based on revenue and volume.
Overview of the Global Professional Indemnity Insurance Market:
The report spread across 90 pages is an overview of the Global Professional Indemnity Insurance Market. These report study based on the Professional…
Modular Construction Market Future Growth Explored in Latest Research Report by …
The report covers a forecast and an analysis of the Modular Construction Market on a global and regional level. The study provides historical data for 2018, 2019, and 2020 along with a forecast from 2019 to 2026 based on revenue and volume.
Overview of the Global Modular Construction Market:
The report spread across 90 pages is an overview of the Global Modular Construction Market. These report study based on the Modular Construction Market. It…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
